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Summary
CD41 T helper cells are a valuable component of the immune response
towards cancer. Unfortunately, natural tumour-specific CD41 T cells occur
in low frequency, express relatively low-affinity T cell receptors (TCRs) and
show poor reactivity towards cognate antigen. In addition, the lack of
human leucocyte antigen (HLA) class II expression on most cancers dictates
that these cells are often unable to respond to tumour cells directly. These
deficiencies can be overcome by transducing primary CD41 T cells with
tumour-specific HLA class I-restricted TCRs prior to adoptive transfer. The
lack of help from the co-receptor CD8 glycoprotein in CD41 cells might
result in these cells requiring a different optimal TCR binding affinity. Here
we compared primary CD41 and CD81 T cells expressing wild-type and a
range of affinity-enhanced TCRs specific for the HLA A*0201-restricted NY-
ESO-1- and gp100 tumour antigens. Our major findings are: (i) redirected
primary CD41 T cells expressing TCRs of sufficiently high affinity exhibit a
wide range of effector functions, including cytotoxicity, in response to
cognate peptide; and (ii) optimal TCR binding affinity is higher in CD41 T
cells than CD81 T cells. These results indicate that the CD41 T cell
component of current adoptive therapies using TCRs optimized for CD81 T
cells is below par and that there is room for substantial improvement.
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Introduction
Cytotoxic CD81 T cells scan peptides displayed by human
leucocyte antigen class I (HLA-I) molecules at the cell sur-
face. This mechanism allows T cells to kill cells that are
infected with pathogens or that show dysregulation of their
normal gene expression. Harnessing T cells for cancer
immunotherapy is highly topical, and has seen much
recent success [1]. One promising approach involves the
transfer of tumour-specific T cell receptors (TCRs) into
patient T cells to redirect them into killing cancer cells
prior to adoptive transfer [2,3]. A potential limitation of
this approach is that naturally occurring tumour-specific T
cells tend to have low sensitivity for cognate peptide anti-
gen as a result of bearing TCRs with weaker binding affinity
than those used to recognize pathogen-derived peptides
[4,5]. As a result, there is much interest in enhancing the
affinity of cancer-specific TCRs in order to optimize their
sensitivity for therapeutic use. Several studies have shown
that the use of enhanced-affinity TCRs can improve the
recognition of tumour cells and optimized receptors for
the HLA A*0201 (HLA A2)-restricted NY-ESO-1157–165
and HLA A*0101 (HLA A1)-restricted MageA3161–169 sys-
tems have been trialled in patients [6–12]. To date, most
work has focused on CD81 T cells due to their capacity to
directly destroy tumour cells. Nevertheless, it is believed
widely that tumour-specific CD41 T cells also play a vital
role in anti-cancer immunity. Having a predominately T
helper type 1 (Th1) cytokine phenotype, tumour-specific
CD41 T cells may provide help in the proliferation, differ-
entiation and maintenance of CD81 T cells in the tumour
microenvironment and act in synergy with local CD81 T
cells to control tumour growth, even though they may not
necessarily have direct cytotoxic abilities [13–16]. It is also
possible that tumour-specific CD41 T cells may promote
epitope spreading by neutralizing the immunosuppressive
effects of the tumour microenvironment. The lack of HLA
class II (HLA-II) expression on most tumours poses a sig-
nificant obstacle to the generation of natural, on-site
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tumour-specific CD41 T cell help. Hence, an attractive
solution to this problem would be to engineer CD41 T cells
so that they can recognize HLA-I restricted cancer peptides
and provide help directly at the tumour site. Such HLA-I
redirected CD41 T cells have been shown to perform a
variety of effector functions, including potent cytokine
production and tumour cell lysis [17–23]. However, the
CD8 co-receptor, absent in CD41 T cells, is known to
provide important roles in T cell activation by stabilizing
interactions of HLA-I with the TCR and optimizing TCR-
mediated signalling via delivery of the protein tyrosine
kinase Lck to the intracellular side of the TCR–CD3 com-
plex [24–26]. This lack of adaptation of CD41 T cells for
recognition of HLA-I might mean that the optimal affinity
and/or dwell time of HLA-I-restricted TCRs might differ
when they are expressed in CD41 and CD81 T cells. We
have demonstrated previously that CD8 controls T cell
cross-reactivity towards HLA-I-restricted peptides [27].
Interaction of CD8 with MHC stabilizes the TCR–peptide
major histocompatibility complex (pMHC) interaction
[26], thereby allowing weaker ligands to be recognized.
CD8 also recruits the key kinase Lck to the cytoplasmic
side of the TCR–CD3 complex and is critical to functional
signalling by weaker ligands [24]. These two functions
combine to allow many more ligands to be recognized in
the presence of CD8 [27]. The greater cross-reactivity of
HLA-I-restricted TCRs in the presence of CD8 suggests
that there may be more opportunity to enhance the affinity
of such TCRs in CD41 T cells before off-target effects are
observed due to cross-recognition of self-peptides [27]. In
support of this notion, experiments in the murine 2C TCR
model system comparing TCRs of two distinct affinities,
CD41 T cells expressing an MHC class I-restricted TCR
with a 1000-fold higher affinity (m33 TCR, KD5 30 nM)
than the wild-type (wt) 2C TCR (KD5 30 lM), were found
to control tumour growth and persisted for longer periods
in the mice, compared to similarly transduced CD81 T
cells, which were deleted in vivo soon after transfer [28,29].
In the human HLA A2-restricted NY-ESO-1157–165 tumour
system, transduced CD81 T cells expressing TCRs with a
binding dissociation constant (KD) of 84 nM were found to
be cross-reactive, while transduced CD41 T cells only
displayed off-target effects at considerably higher
affinities [30].
In this study we evaluated formally the optimal binding
affinity of HLA-I-restricted TCRs in CD41 and CD81 T
cells by using a range of high-affinity TCRs specific for
two well-studied and therapeutically important HLA
A2-restricted tumour antigens, NY-ESO-1157–165 and
gp100280–288. Our results confirm that the TCR affinity
required for optimal CD41 T cell effector function is
higher than that required for CD81 T cells, and show that
CD41 T cells expressing higher-affinity TCRs displayed
potent effector function.
Materials and methods
Peptides
All peptides were purchased from PeptideSynthetics (Pep-
tide Protein Research Ltd, Bishops Waltham, UK) in
lysophilized form and reconstituted in dimethylsulphoxide
(DMSO) (Sigma-Aldrich, Poole, UK) to a stock solution of
4 mg/ml in DMSO and divided into aliquots such that the
number of freeze–thaw cycles was kept to a minimum.
Working concentrations of peptides were made in RPMI
supplemented with 100 U/ml penicillin (Life Technologies,
Paisley, UK), 100 lg/ml streptomycin (Invitrogen, UK)
and 2 mM L-glutamine (Life Technologies). The peptides
used in activation assays were SLLMWITQC (SLL,
NY-ESO-1157–165 epitope) and heteroclitic peptide
YLEPGPVTV (YLE, gp100280–288 epitope).
T cells and target cell lines
HLA A*02011 (HLA A2), HLAnull C1R cells [24,31] and
HLA A21 T2 cells [32,33] were cultured in RPMI supple-
mented with penicillin, streptomycin, L-glutamine and
10% heat-inactivated fetal calf serum (FCS) (GIBCO, Paisley,
UK) (R10 medium). T cells were maintained in R10 with
25 ng/ml interleukin (IL)-15 (PeproTech EC, London,
UK), 200 IU/ml IL-2 (PeproTech EC) and 2.5% Cellkines
(Helvetica Healthcare, Geneva, Switzerland).
Generation of CD81 and CD41 T cell cultures for
lentiviral transduction
Blood bags from anonymous healthy donors were obtained
from the Welsh Blood Service (Pontyclun, UK). Lympho-
cytes were purified using lymphoprep (Axia-Shield, Dun-
dee, UK) and typed for HLA A2 by antibody staining.
CD81 and CD41 T cells were selected positively by CD8
and CD4 microbeads, respectively, purified through a mag-
netic affinity cell sorting (MACS) MS column (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) and resus-
pended at 106/well in R10 with IL-15, IL-2 and Cellkines.
Cells were activated overnight with aCD3/aCD28 Dyna-
beads (Invitrogen) at a bead to cell ratio of 3:1 before lenti-
viral transduction.
Lentivirus generation and transduction of CD81 and
CD41 T cells
HLA A21 primary T cells were transduced with lentivirus
expressing TCRs bearing various affinities for HLA
A2-restricted tumour antigens NY-ESO-1157–165
(SLLMWITQC) and gp100280–288 (YLEPGPVTV). Wild-
type and high-affinity TCR mutants for NY-ESO-1157–165
and gp100280–288 were generated in this study or as
described previously [9,30,34]. The panel of TCR lentiviral
constructs and their biophysical data are presented in
Table 1. The lentiviral transduction system utilized in these
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studies was kindly provided by James L. Riley (University
of Pennsylvania, USA) and was described previously [9].
Briefly, lentiviral vector plasmids bearing each TCR con-
struct were combined with packaging plasmids pRSV.REV,
pMDLg/pRRE and pVSG-V before transfection of 293T/17
cells (ATCC, Manassas, VA, USA) using the Express-in
transfection reagent (Open Biosystems, Huntsville, AL,
USA). Supernatant containing lentiviral particles was col-
lected after 24- and 48-h incubations and concentrated by
ultracentrifugation. Activated primary CD41 and CD81 T
cells (106 in 1 ml) were transduced with 1 ml concentrated
lentivirus. Following 3 days’ incubation, the efficiency of
transduction was determined by flow cytometry after stain-
ing with relevant tetramer and aVb TCR antibody, and
Dynabeads were removed by magnet on day 5 following
transduction.
Measurement of soluble factors by enzyme-linked
immunosorbent assay (ELISA)
T cells were resuspended at 106/ml in RPMI supplemented
with penicillin, streptomycin, L-glutamine and 2% FCS
(R2 media) overnight. Target cells were pulsed with peptide
for 1 h and washed to remove unbound peptide before T
cells were added at an effector : target ratio of 1:2. After
overnight incubation, tissue culture plates were centrifuged
briefly to pellet cells, and the culture supernatant was har-
vested for measurement of lymphokines macrophage
inflammatory protein (MIP)21b, interferon (IFN)-g,
tumour necrosis factor (TNF)-a and IL-2 by ELISA,
performed according to the manufacturer’s protocol (R&D
Systems, Weisbaden, Germany).
Monoclonal antibodies, amine reactive dyes and
tetrameric complexes
Directly conjugated monoclonal antibodies were obtained
as follows: (i) aMIP-1b-phycoerythrin (PE), aCD107a-PE
and aCD69-PE (BD Biosciences, Oxford, UK); (ii) aTCR
Vb 13.1-fluorescein isothiocyanate (FITC) and aTCR Vb
17-FITC (Beckman Coulter, High Wycombe, UK); (iii)
live/dead fixable Aqua dead stain (Molecular Probes, Invi-
trogen, UK); (iv) aCD3-Pacific blue, aCD3-PEcyanin 7
(Cy7), aCD4-allophycocyanin (APC) H7, aCD8-APC H7,
aCD19-Brilliant Violet 521, aIFN-g-PECy7, aTNF-a-
PerCPCy5.5, aIL2-APC, aperforin-Brilliant Violet 421
(clone D48) and agranzyme B-AlexFlour 647 (Biolegend,
London, UK); and (v) aCD3-PCP (Miltenyi Biotech).
Soluble peptide-MHCI (pMHCI) monomers were gener-
ated and biotinylated as described previously [26,35] and
tetramers for SLLMWITQC/HLA A2 and YLEPGPVTV/
HLA A2 were produced by adding streptavidin conjugated
with APC (Molecular Probes, Invitrogen) [35]. The HLA
type of lymphocytes isolated from blood bags was deter-
mined using directly conjugated aHLA A2-FITC (Serotec,
Oxford, UK).
Intracellular cytokine staining
T cells were resuspended at 106/ml in R2 media overnight.
Target cells were pulsed with peptide for 1 h and washed to
Table 1. Biophysical data for the NY-ESO157-165 and gp100280-288 T cell receptor systems
Specificity
TCR
(a/b)
Half life
(t1/2, s)
KD
(lM)
Kon
(M21s21)
Koff
(s21)
NY-ESO-1157-165 wt/wt 2.2 9.3 3.433 10
4 3.13 1021
(HLA-A*0201) wt/c263 9.6 1.13 6.363 104 7.23 1022
c259/wt 19 0.730 4.873 104 3.63 1022
wt/c268 33 0.16 1.283 105 2.13 1022
wt/c266 40.8 0.28 5.823 104 1.73 1022
c259/c263 74 0.12 7.73 104 9.43 1023
c12/c2 173 0.45 93 103 43 1023
wt/c51 495 0.025 5.43 104 1.43 1023
c58/c61 68,100 2.63 1025 5.73 105 2.723 1025
gp100280-288 wt/wt 1.1 18.5 3.43 10
4 6.353 1021
(HLA-A*0201) 19/wt 0.7 7.9 1.253 105 9.93 1021
20/wt 0.88 4 1.973 105 7.93 1021
wt/FGA 3.6 2.6 7.53 104 1.943 1021
wt/YGA 5.7 1.9 6.53 104 1.223 1021
wt/WGA 8.5 1.1 7.43 104 8.23 1022
wt/G2I 10.2 0.402 2.753 105 6.833 1022
wt/G4N 60.3 0.035 3.253 105 1.153 1022
wt/T3V 89.2 0.026 3.043 105 7.83 1023
TCR, T cell receptor; KD, dissociation constant (affinity); Kon, association rate; Koff, dissociation rate; wt, wildtype. The HLA-restriction for
each system is indicated in brackets. TCRs shown in grey highlight were not included in the study because the cells were not viable or because
the TCR mutations meant that they could not be tracked with Vb antibody.
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remove unbound peptide before adding T cell effectors at
an effector : target ratio of 1:2 together with 1 ll/ml
brefeldin A (Sigma-Aldrich) and 0.35 ll/ml monensin (BD
Biosciences). After 5 h of antigen stimulation, cells were
washed and stained sequentially with the Aqua live/dead
stain to exclude dead cells and then with antibodies for sur-
face molecules (CD3 and CD19). Cells were fixed and per-
meabilized using the BD Cytofix/Cytoperm kit and stained
intracellularly for CD4 or CD8, TCR-Vb, MIP-1b, IFN-g,
TNF-a and IL-2. Stained cells were acquired using BD FACS-
DIVA version 8 (BD Biosciences) on the BD FACS Canto II
(BD Biosciences). Cell population gates were set using fluo-
rescent minus one (FMO) staining controls. For TCR-
transduced cells, events were gated on relevant Vb1CD41
or Vb1CD81 events for effector function analysis after
Boolean gating using FlowJo version 7.6.4 (Treestar Inc.,
Ashland, OR, USA). Non-transduced cells were gated on
CD31CD41 or CD31CD81 events. A representative gating
strategy is shown in Supporting Information, Fig. S1.
Degranulation assay
T cells were resuspended at 106/ml in R2 media overnight.
T2 target cells were pulsed with peptide for 1 h and washed
to remove unbound peptide before adding T cell effectors
at an effector : target ratio of 1:2 together with 1 ll/ml bre-
feldin A (Sigma-Aldrich), 0.35 ll/ml monensin (BD Bio-
sciences) and 10 ll/ml aCD107a-PE. After 5 h of antigen
stimulation, cells were washed and stained sequentially
with the Aqua live/dead stain to exclude dead cells and
then with antibodies for surface molecules (CD3 and
CD19). Cells were fixed and permeabilized using the BD
Cytofix/Cytoperm kit and stained intracellularly for CD4
or CD8, TCR-Vb, granzyme B and perforin. Stained cells
were acquired and analysed as described above.
Target cell lysis by 51chromium release (51Cr) assay
For chromium release assays, 2 3 103 HLA A21 T2 target
cells per well were labelled with 30 lCi of 51Cr (Perkin
Elmer Life Sciences, Waltham, MA, USA) per 106 cells for
1 h at 378C. Targets were cultured alone to determine spon-
taneous release and with Triton X-100 (Sigma-Aldrich) at a
final concentration of 5% to determine total release. Pep-
tides were added to assay plates at varying concentrations
and T cells were plated out in a final volume of 200 ll of
R10 at effector : target ratios of 5:1 before incubation for
4 h at 378C. For each sample, 15 ll of supernatant was har-
vested after incubation and mixed with 150 ll of OptiPhase
supermix scintillation mixture (PerkinElmer Life Sciences).
Data were acquired using a liquid scintillator and lumines-
cence counter (MicroBeta TriLux; PerkinElmer Life Scien-
ces) with MicroBeta Windows Workstation software
(PerkinElmer Life Sciences). Specific lysis was calculated
according to the following formula: (experimental
release – spontaneous release/total release – spontaneous
release) 3 100.
Results
Redirecting primary CD41 T cells with enhanced
affinity HLA-I-restricted tumour-specific TCRs
Primary HLA A21 CD41 and CD81 T cells were trans-
duced with lentiviruses expressing the wild-type and
enhanced affinity HLA-I-restricted NY-ESO-1 and gp100
TCRs listed in Table 1. CD81 T cells expressing the
extremely high-affinity NY-ESO-1 c58/c61 TCR (KD5 26
pM) were not viable in culture and could not be studied, in
contrast to the CD41 T cells transduced with the same
high-affinity TCR. This is attributed probably to fratricide,
as described previously [9]. CD81 and CD41 T cells trans-
duced with two gp100-specific TCRs (wt/G2I,
KD5 402 nM; and wt/T3V, KD5 26 nM) could not be
stained with Vb17 antibody, due probably to the location
of the TCR mutations (Fig. 1). They were hence excluded
from our study, as the lack of antibody staining made it dif-
ficult to assess the expression levels of wt/G2I and wt/T3V
TCRs in functional assays.
Primary CD41 and CD81 T cells transduced with all
TCRs studied were stained with cognate pMHCI tetramer
and antibody specific for the relevant TCR-Vb chain (Fig.
1). Apart from wt/G2I and wt/T3V TCRs from the gp100
panel, all cells stained with the relevant TCR-Vb antibody
following transduction; staining levels in the NY-ESO-1
system varied between 24–50% and 9–37% in the gp100
system. CD81 T cells transduced with all NY-ESO-1 TCRs
including the wild-type TCR could be stained with cognate
SLLMWITQC/HLA A2 tetramers. In contrast, only CD41
T cells with the wt/c51 and c58/c61 TCRs (KDs5 25 nM
and 26 pM, respectively) could be stained with these
reagents (Fig. 1a). Similar results were observed with the T
cells transduced with gp100 TCRs, except that here CD81
T cells with affinities lower than 2.6 lM (wt/FGA TCR)
did not stain well with cognate YLEPGPVTV/HLA A2 tet-
ramer (Fig. 1b). As with the NY-ESO-1 TCRs, only the
CD41 T cells expressing high-affinity gp100 TCRs (wt/G2I,
wt/G4N and wt/T3V) stained with gp100 tetramer. These
results serve to highlight the important role that the CD8
co-receptor plays in pMHCI multimer binding [26,36].
CD41 T cells transduced with all NY-ESO-1 TCRs
responded to C1R targets transduced with HLA A*0201
(C1R-A2) and pulsed with 100 nM cognate SLLMWITQC
peptide but did not respond to untransduced A2-C1R tar-
gets (Supporting information, Fig. S2). Production of MIP-
1b increased as far as the c259/263 TCR (KD5 120 nM),
with lower levels of production seen with higher-affinity
TCRs. Some background activation could be observed with
substantially enhanced TCRs (Supporting information, Fig.
S2). Overall, these data show that CD41 T cells can be
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Fig. 1. CD41 T cells transduced with high affinity anti-tumour T cell receptors (TCRs) stain with human leucocyte antigen (HLA)-I tetramer in
the absence of the CD8 co-receptor molecule. HLA A21 CD81 and CD41 T cells were transduced with NY-ESO-1 (a) and gp100 (b) TCRs and
the transduction efficiency was assessed by TCR Vb13.1/Vb17 antibody staining, or by cognate tetramer. Cells were gated on live CD31CD81 or
CD31CD41 populations. Values reflected here are from a single representative experiment of at least three independently performed experiments.
UNT 5 non-transduced cells.
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Fig. 2. Human leucocyte antigen (HLA)-I T cell receptor (TCR)-transduced CD41 T cells exhibit a polyfunctional effector profile upon peptide
stimulation. Stimulation of HLA A21 CD81 and CD41 T cells transduced with NY-ESO-1 (a) and gp100 (b) TCRs with or without the
indicated concentrations of SLLMWITQC (SLL) and YLEPGPVTV (YLE) peptide, respectively, pulsed on HLA A21 T2 target cells. Pie charts
reflect proportion of cells exhibiting effector functions measured by intracellular staining with the area of each segment representing the
proportion of cells displaying between 0 (grey) to 4 (red) functions. Cells are gated as described in Supporting information, Fig. S1. Effector
functions measured were macrophage inflammatory protein (MIP)-1b, interferon (IFN)-g, tumour necrosis factor (TNF)-a and interleukin
(IL)-2 production. The biophysical data relating to the TCRs are described in Table 1. Values reflected here are from a single representative
experiment of two independently performed experiments. UNT 5 non-transduced cells.
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redirected to recognize an HLA-I-restricted peptide by
TCR transduction with a relevant TCR and indicate that
the optimal affinity/dwell time for recognition is higher
than the wild-type TCR isolated from a CD81 T cell. We
next set out to compare the optimum TCR affinity/half-life
in CD41 and CD81 T cells expressing NY-ESO-1 and
gp100 TCRs.
Comparison of TCR affinity optima in CD41 and
CD81 T cells transduced with HLA-I-restricted TCRs
T cells expressing similar amounts of HLA-I-restricted
TCRs, as determined by CD3 and relevant Vb staining,
were incubated with cognate peptide-pulsed T2 targets
(HLA A*02011) and their activation profiles were com-
pared via intracellular cytokine staining (Fig. 2). Figure 2a
shows effector function responses for cells transduced with
NY-ESO-1 TCRs in the form of pie charts, as described
previously [9]. CD81 T cells transduced with the second
highest-affinity TCR (wt/c51; KD5 25 nM) failed to
respond well to 1027 M cognate peptide, suggesting that
this TCR was beyond optimal in this system, as noted pre-
viously [9]. Simultaneous direct comparison with CD41 T
cells from the same individual showed some contrasting
results, as CD41 T cells expressing the c58/c61 TCR were
viable. However, these cells responded to T2 targets in the
absence of exogenous peptide, suggesting that they were
able to see a self-peptide in the context of HLA A2. Fur-
thermore, CD41 T cells transduced with the wild-type NY-
ESO-1 TCR failed to respond to target cells pulsed with
100 nM cognate peptide, highlighting the importance of
the CD8 co-receptor with natural-affinity HLA-I-restricted
TCRs as previously reported in the murine system [37].
Results with CD41 and CD81 T cells transduced with the
gp100 TCRs were similar, but more exaggerated (Fig. 2b).
Here, CD81 T cells expressing the highest-affinity TCR
(wt/3G4N; KD 5 35 nM) reacted to targets in the absence
of cognate YLEPGPVTV peptide, while CD41 T cells trans-
duced with the same TCR maintained peptide specificity.
The wild-type gp100 TCR (KD 5 18.5 lM) functioned well
in CD81 T cells, but CD41 T cells expressing this TCR
failed to respond even to 100 lM peptide. Indeed, even
CD41 T cells transduced with the affinity-enhanced 20t/wt
TCR (KD5 4 lM) failed to recognize peptide-pulsed tar-
gets. Overall, these results suggest that CD41 T cells require
higher-affinity TCRs with longer TCR-peptide-HLA dwell
times for recognition of HLA-I-restricted peptides than
similarly transduced CD81 T cells. At the other end of the
affinity spectrum, CD41 T cells can tolerate higher-affinity
HLA-I-restricted TCRs than CD81 T cells while still main-
taining peptide specificity. In combination, these results
suggest that the affinity of HLA-I-restricted TCRs required
for optimal function is higher in CD41 T cells than in
CD81 T cells.
Effector function of CD41 and CD81 T cells
transduced with HLA-I-restricted TCRs
We next examined how TCR-transduced CD41 and CD81
T cells compared in terms of IFN-g, MIP-1b, TNF-a and
IL-2 production in response to a log-fold titration of exog-
enous cognate peptide (Fig. 3). Naturally occurring
tumour-specific HLA-II-restricted CD41 T cells and those
engineered to express HLA-I-restricted tumour TCRs have
been reported to exhibit a mainly Th1 phenotype, where
cells typically produce IFN-g, TNF-a and IL-2 but not IL-
4, IL-5 or IL-10 [13–15,21]. In both the NY-ESO-1 and
gp100 panels, CD41 and CD81 T cells made similar maxi-
mal amounts of IFN-g. Both cell types produced MIP-1b
in response to peptide, with the maximal response being
slightly higher in CD41 T cells with the optimal NY-ESO-1
TCR. In contrast, CD81 T cells made more MIP-1b than
CD41 T cells with the respective optimal gp100 TCR.
CD41 T cells were able to produce much higher levels of
TNF-a and IL-2 than CD81 T cells in response to peptide.
In general, the wt/c263 TCR (KD1 lM) appeared optimal
in CD81 T cells and c12/c2 TCR (KD5 0.45 lM) in CD4
1
T cells with the NY-ESO-1 system. Similarly, the optimal-
affinity gp100 TCR was higher in CD41 T cells (wt/G4N;
KD5 35 nM) than in CD8
1 T cells (20/wt; KD5 4 lM).
Importantly, the natural-affinity TCR was suboptimal in
both systems and with all effector readouts. MIP-1b was
the most sensitive readout for CD81 T cells with both
TCRs in accordance with our previous studies, showing
that this b-chemokine provides the most sensitive readout
for a wide range of CD81 T cell clones [38–40]. Indeed,
background MIP-1b production was observed with the wt/
c51 TCR even in the absence of cognate peptide. Unexpect-
edly, MIP-1b was also the most sensitive readout for bulk
CD41 T cells transduced with HLA-I-restricted TCRs. Sim-
ilar results were observed when the HLA A21 NY-ESO-11
tumour cell line MEL624.38 was used as a target, confirm-
ing that CD41 T cells could be reprogrammed to recognize
tumour cells directly by producing Th1-type cytokines
(Supporting information, Fig. S3).
Overall, our findings support reports of tumour-specific
CD41 T cells displaying a Th1 phenotype, although we did
not formally rule out the production of Th2 type cytokines.
Our results also show that redirected CD41 T cells are able
to exhibit effector functions which are absent in CD81 T
cells expressing the same antigen-specific TCRs.
HLA-I-redirected CD41 T cells with enhanced TCRs
exhibit efficient target lysis
As described above, tumour-specific CD41 T cells play an
important role in the provision of help to CD81 T cells in
the tumour environment. However, HLA-I-redirected
CD41 T cells might also be capable of direct, efficient
tumour lysis. We next compared the ability of CD41 T cells
expressing both NY-ESO-1 and gp100 TCRs to lyse
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antigen-bearing targets to that of CD81 T cells (Fig. 4). As
expected, transduced CD81 T cells proved to be efficient
killers of T2 targets pulsed with both cognate antigens. NY-
ESO-1 TCR-transduced CD41 T cells could also lyse target
cells, but they required a higher affinity TCR than was nec-
essary for CD81 T cell mediated lysis. The maximal specific
lysis of 50% observed with NY-ESO-1 TCR-transduced
CD41 T cells was lower than the 90% maximum seen
with the wild-type TCR in CD81 cells. Our findings were
similar in the gp100 system, although here, CD41 T cells
transduced with the highest-affinity wt/G4N TCR tested
(KD 5 35 nM) were almost as efficient at lysing targets as
similarly transduced bulk CD81 T cells.
HLA-I-redirected CD41 T cells with enhanced TCRs
express granzyme B and perforin and degranulate in
response to cognate antigen
Observations that engineered HLA-I-restricted CD41 T
cells could directly kill peptide-pulsed or tumour targets
Fig. 3. Human leucocyte antigen (HLA)-I-restricted NY-ESO-1 and gp100 T cell receptor (TCR)-transduced CD41 T cells exhibit a different
cytokine profile compared to CD81 counterparts in response to cognate antigen stimulation. CD81 and CD41 T cells transduced with the NY-
ESO-1 (a) and gp100 (b) TCRs were stimulated with titrating concentrations of SLLMWITQC (SLL) and YLEPGPVTV (YLE) peptide,
respectively, loaded on HLA A21 T2 target cells. After overnight incubation, the culture supernatant was harvested for measurement of interferon
(IFN)-g, macrophage inflammatory protein (MIP)-1b, tumour necrosis factor (TNF)-a and interleukin (IL)-2 by enzyme-linked immunosorbent
assay (ELISA). The biophysical data of the higher-affinity TCRs are described in Table 1. Values reflected here are from a single representative
experiment of two independently performed experiments. UNT 5 non-transduced cells.
Fig. 4. Human leucocyte antigen (HLA)-I-restricted CD41 T cells are cytotoxic towards peptide-pulsed targets. CD81 and CD41 T cells
transduced with the NY-ESO-1 (a) and gp100 (b) T cell receptors (TCRs) were incubated with HLA A21 T2 targets previously pulsed with
51chromium and loaded with titrating concentrations of SLLMWITQC (SLL) and YLEPGPVTV (YLE) peptide, respectively. Culture supernatant
was collected after 4 h incubation and measured for 51chromium release. The biophysical data of the higher-affinity TCRs are described in
Table 1. Values reflected here are from a single representative experiment of at least two independently performed experiments. UNT 5 non-
transduced cells.
M. P. Tan et al.
132 VC 2016 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology, 187: 124–137
have been reported previously, but the mechanism of target
cell killing varies across studies [17–19,21,41]. Hence, we
next compared the mechanisms that HLA-I-redirected
CD41 and CD81 T cells might be use to lyse target cells
and examined the expression of CD107a, granzyme B and
perforin in the transduced CD41 and CD81 T cells to
determine whether the observed target cell killing could be
mediated by lytic granule formation. We observed distinct
and marked degranulation upon peptide activation for
both the NY-ESO-1 and gp100 TCR-transduced CD81 T
cells, as inferred by increased expression of CD107a (Fig.
5). Granzyme B production was also increased upon
Fig. 5. Human leucocyte antigen (HLA)-I-restricted CD41 T cells kill via a lytic granule-mediated mechanism. HLA A21 CD81 and CD41 T
cells transduced NY-ESO-1 (a) and gp100 (b) T cell receptors (TCRs) were incubated with HLA A21 T2 target cells with or without 102 6 M
SLLMWITQC (SLL) and YLEPGPVTV (YLE) peptide, respectively, for 5 h. They were then examined for surface CD107a and intracellular
granzyme B and perforin expression by flow cytometry. Cells were gated on live CD31CD81 or CD31CD41 populations also expressing TCR
Vb13.1 or Vb17 for NY-ESO-1 and gp100 TCRs, respectively. Non-transduced cells (UNT) were gated on live CD31CD81 or CD31CD41
populations. Values reflected here are from a single representative experiment of three independently performed experiments.
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activation in both TCR-transduced CD41 and CD81 T
cells. Results between CD41 and CD81 T cells differed
when perforin levels were examined. While all CD81 trans-
duced T cells expressed high levels of perforin, only 40%
of CD41 transduced T cells were found to express perforin,
but this level increased after cells were incubated with HLA
A21 targets expressing cognate antigen indicating that per-
forin expression can be induced by antigen in some trans-
duced CD41 T cells. Our results indicate that CD41 T cells
redirected to HLA-I-restricted tumour antigens can kill
tumour targets by a lytic granule-mediated mechanism.
Discussion
The use of affinity-enhanced TCRs in adoptive cell transfer
for cancer immunotherapy is proving promising in the
clinic [42–44]. Much attention has been focused upon
tumour-specific CD81 T cells, due to the fact that they
have the potential to directly kill tumour cells. However, it
is recognized increasingly that tumour-specific CD41 T
cells also play an instrumental role in tumour control. Sev-
eral obstacles preclude easy exploitation of natural
tumour-specific HLA-II-restricted CD41 T cells. First,
such cells are typically present at very low frequency. Sec-
ondly, they tend to express relatively low-affinity TCRs
compared to anti-pathogen TCRs, rendering them less
sensitive to cognate antigen [5]. Thirdly, very few natural
tumour-specific HLA-II-restricted peptide antigens have
been defined. Finally, most tumours express HLA-II
poorly or not at all, thus limiting the potential for direct
help at the tumour site. In addition, unlike tumour-
specific CD81 T cells, anti-tumour CD41 T cells may lack
direct cytotoxic abilities [16]. In order to overcome these
limitations, HLA-I-restricted tumour TCRs, usually of
native affinity, have been expressed on CD41 T cells such
that they can be redirected to recognize HLA-I-restricted
tumour antigens and contribute to the anti-tumour
immunity [17–21].
Here, we evaluated the impact of expressing a range
of HLA-I-restricted tumour-specific TCRs with different
affinities for cognate antigen on CD41 T cells and
compared the functional efficacy of these redirected
CD41 T cells with CD81 T cells expressing the same
TCRs. Using two well-studied HLA A2-restricted
tumour systems, CD41 T cells transduced with
enhanced affinity TCRs were shown to be potent effec-
tor cells in response to cognate antigen and exhibited
direct tumour lysis.
There is much support in the literature for the synergis-
tic effects of tumour-specific CD41 and CD81 T cells
within the cancer microenvironment [12,14,16,17]. In our
study, polyclonal CD41 primary T cells expressing high-
affinity HLA-I-restricted NY-ESO-1 and gp100-specific
TCRs produce high levels of TNF-a and IL-2. These cyto-
kines were produced in low abundance by similarly
transduced CD81 T cells from the same individual(s). This
finding is consistent with other studies showing that CD41
T cells redirected to HLA-I-restricted tumour antigens pro-
duced more IL-2 compared to transduced CD81 T cells
[19,22]. Indeed, others have reported that paracrine cyto-
kine production can enhance the anti-tumour functions of
native or even high-affinity CD81 T cells by increasing
CD81 T cell accumulation at the tumour site, increasing
CD81 T cell tumour killing (e.g. by up-regulation of gran-
zyme and perforin) and CD81 T cell proliferation
[12,14,16,17]. Additional IFN-g release from CD41 T cells
may also up-regulate HLA-I and HLA-II molecules on the
tumour cell surface, which may result in the recruitment of
more tumour-specific CD81 and CD41 T cells to the dis-
ease site [45,46].
Our data show that, in general, HLA-I-redirected CD41
T cells required a TCR with an affinity higher than that
needed by CD81 T cells for optimal anti-tumour effector
function. CD41 T cells transduced with optimal affinity
TCRs were at least as sensitive to low antigen concentra-
tions as CD81 T cells. This finding contrasts with studies
which reported that CD41 T cells made to express HLA-I-
restricted TCRs are markedly less sensitive than CD81 T
cells. For example, Xue et al. reported a 10-fold reduction
in peptide sensitivity when HLA-I-restricted Epstein–Barr
virus (EBV) and cytomegalovirus (CMV)-specific TCRs
were expressed on CD41 T cells; and when a HLA-I-
restricted influenza nucleoprotein-specific TCR was
expressed on CD41 T cells, Morris et al. found that CD41
T cells were also less sensitive to peptide than CD81 T cells
[22,23]. Both these studies found that the sensitivity of
transduced CD41 T cells could be restored when the CD8
molecule was also transferred. Our results suggest that
transduction of CD41 T cells with enhanced-affinity TCRs
can largely bypass the need for the CD8 co-receptor. These
findings are supported by those of Chhabra et al., who
expressed a high-affinity HLA-I-restricted MART1 TCR
(KD in the nM range) on CD4
1 T cells and reported that
the transduced CD41 T cells were as sensitive as CD81 T
cells in producing IFN-g in the presence of peptide-pulsed
targets [21]. Also, co-transfer of the CD8 molecule to
CD41 T cells expressing high-affinity HLA-I-restricted
TCRs has been shown to confer cross-reactivity to self [30].
In combination, the data to date suggest that HLA-I-
restricted TCRs require different affinities and/or dwell
times for optimal function in CD41 T cells compared to
CD81 T cells.
In conclusion, we report that polyfunctional cytotoxic
anti-tumour CD41 T cells can be generated through the
transfer of enhanced affinity TCRs specific for HLA-I-
restricted tumour antigens. The TCR affinity required for
the optimal anti-tumour functionality of CD41 T cells is
higher than that required for CD81 T cells. CD41 T cells
redirected to recognize HLA-I-restricted antigens with
optimal TCRs can respond to low peptide densities,
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making them attractive for immunotherapy, as tumour-
associated peptides are usually present at the cell surface at
very low copy numbers of fewer than 50 copies per cell
([47] and unpublished). As both CD41 and CD81 T cell
responses are believed to be beneficial for tumour clear-
ance, it could be advantageous to include HLA-I-redirected
CD41 T cells in adoptive cell transfer regimens in addition
to CD81 T cells. Our results suggest that the most benefi-
cial therapy might involve engineered CD41 and CD81 T
cells expressing different TCRs with the appropriate
TCR : pMHC affinities to allow optimal, synergistic func-
tion of both T cell subsets.
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Fig. S1. Representative gating strategy used in intracellu-
lar cytokine staining experiments to assess T cell poly-
functionality. Briefly, T cells were incubated with antigen
and target cells after which surface and intracellular stain-
ing was performed. Lymphocytes were identified by their
scatter profiles, and live CD31 cells were identified after
excluding aggregates and Aqua1/CD191 cells. CD8/41
Vb13.11 T cells [here indicating cells expressing NY-
ESO-1 T cell receptor cells (TCRs)] were identified and
cells producing interferon (IFN)-g, tumour necrosis fac-
tor (TNF)-a, interleukin (IL)-2 and macrophage inflam-
matory protein (MIP)-1b were identified after Boolean
gating. Polyfunctionality for non-transduced CD81 and
CD41 T cells was performed by gating on CD31CD8 or
CD31CD41 cells as a total population.
Fig. S2. CD41 T cells expressing high-affinity T cell
receptors (TCRs) recognizing NY-ESO-1157–165 tumour
antigen respond to peptide (SLLMWITQC, SLL) stimula-
tion in the context of HLA-I. CD41 T cells transduced
with the panel of NY-ESO-1157–165 TCRs were activated
with human leucocyte antigen (HLA)-A21C1R target cells
(A21C1R) or HLAnull C1R cells (A2-C1R) which were
either pulsed with 1027 M SLL peptide or not. After
overnight incubation, culture supernatant was harvested
and the concentration of MIP-1b was determined by
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enzyme-linked immunosorbent assay (ELISA).
UNT 5 non-transduced cells.
Fig. S3. CD41 T cells expressing NY-ESO-1 T cell recep-
tors (TCRs) respond to a melanoma tumour cell line.
CD81 and CD41 T cells expressing NYESO-1 TCRs were
incubated with or without the NY-ESO-11 melanoma cell
line MEL624.38 (MEL624) at the effector (E) to target
(T) ratio of 5:1. After overnight incubation, culture
supernatant was collected and assayed for the presence of
interferon (IFN)-g and interleukin (IL)-2 by enzyme-
linked immunosorbent assay (ELISA). UNT 5 non-
transduced cells.
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